BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that Stephen G. Dilly, M.B.B.S., Ph.D., Chief Executive Officer of Aimmune, will present a company overview at two upcoming investor conferences in June as follows:
- Goldman Sachs 37th Annual Global Healthcare Conference on Thursday, June 9, 2016, at 8:40 a.m. Pacific Time in Rancho Palos Verdes, California
- JMP Securities Life Sciences Conference on Wednesday, June 22, 2016, at 11:30 a.m. Eastern Time in New York, New York
The live webcasts of the presentations will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. Archived replays of the webcasts will be available for approximately 30 days.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) system, an approach to oral immunotherapy (OIT), uses rigorously characterized product candidates with gradual, controlled up-dosing protocols to obtain clinically meaningful desensitization to food allergens. Aimmune’s first CODIT product, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age. Aimmune’s Phase 3 trial of AR101, PALISADE, is now enrolling patients. For more information, please see www.aimmune.com.